# Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus

Lydia Zorn-Pauly<sup>1</sup>, Anne Sae Lim von Stuckrad<sup>2</sup>, Jens Klotsche<sup>3</sup>, Thomas Rose<sup>1</sup>, Tilmann Kallinich<sup>2,3</sup>, Philipp Enghard<sup>4</sup>, Lennard Ostendorf<sup>3,4</sup>, Marie Burns<sup>3</sup>, Thomas Doerner<sup>1</sup>, Christian Meisel<sup>5</sup>, Udo Schneider<sup>1</sup>, Nadine Unterwalder<sup>5</sup>, Gerd Burmester<sup>1</sup>, Falk Hiepe<sup>1</sup>, Tobias Alexander<sup>1,3\*</sup>, Robert Biesen<sup>1\*</sup>

KEYWORDS: SLE, interferon, biomarker, diagnosis, CD169, SIGLEC1

#### Address correspondence and reprint request:

Dr. med. Robert Biesen
Department of Rheumatology and Clinical Immunology
Charité University Hospital
Charitéplatz 1
D-10117 Berlin – Germany

E-mail: Robert.Biesen@charite.de

<sup>&</sup>lt;sup>1</sup>Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

<sup>&</sup>lt;sup>2</sup>Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité University Medicine Berlin, Berlin, Germany.

<sup>&</sup>lt;sup>3</sup>German Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany

<sup>&</sup>lt;sup>4</sup>Department of Nephrology and Intensive Care Medicine, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

<sup>&</sup>lt;sup>5</sup>Institute for Medical Immunology, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

<sup>\*</sup>Contributed equally

# **ABSTRACT**

**Objectives**: To evaluate and compare the diagnostic accuracy of SIGLEC1, a surrogate marker of type I IFN, with established biomarkers in an inception cohort of systemic lupus erythematosus (SLE).

**Methods**: SIGLEC1 was analysed by flow cytometry in 232 patients referred to our institution with suspected SLE between October 2015 and September 2020.

**Results**: SLE was confirmed in 76 of 232 patients (32.8%) according to the 2019 EULAR/ACR classification criteria and their SIGLEC1 values were significantly higher compared to patients without SLE (p<0.0001). A sensitivity of 98.7 %, a specificity of 82.1 %, a negative predictive value (NPV) of 99.2 % and a positive predictive value (PPV) of 72.8 % were calculated for SIGLEC1. Adjusted to the highest reported prevalence of SLE, the NPV and PPV were > 99.9 % and 0.1 %, respectively. Using ROC analysis and Delong testing, the area under the curve (AUC) for SIGLEC1 (AUC=0.95) was significantly higher than for ANA (AUC=0.88, p=0.031), C3 (AUC=0.83, p=0.001) and C4 (AUC=0.83, p=0.002) but not for anti-dsDNA antibodies (AUC=0.90, p=0.163).

**Conclusion**: IFN-I pathway activation is detectable in almost all newly diagnosed SLE patients. Thus, a negative test result for SIGLEC1 is powerful to exclude SLE in suspected cases.

# INTRODUCTION

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a complex aetiology, mostly affecting women of childbearing age. The highest prevalence worldwide was reported in a national survey in the USA, with 241 cases per 100000 inhabitants [1].

Type-I interferon (IFN-I) plays a pivotal role in the disease pathogenesis and the type I interferon receptor antagonist anifrolumab had recently been approved by the FDA for the treatment of SLE. Among the multitude of interferon-stimulated genes, we have previously identified SIGLEC1 (sialic acid-binding immunoglobulin-like lectin-1, CD169), an adhesion molecule restricted to cells of the monocyte lineage, as a surrogate marker for activation of the IFN-I pathway [2]. Subsequent studies indicated that SIGLEC1 on monocytes correlates with disease activity and reflects response to targeted treatment approaches in SLE [3-5].

Although commonly determined by several centres utilizing different techniques and surrogate markers, little is known about the IFN-I activity during onset of the disease. Therefore, we aimed to investigate the diagnostic utility of the IFN-I surrogate marker SIGLEC1 in patients with suspected SLE.

# **PATIENTS AND METHODS**

In this retrospective study, SIGLEC1 was investigated in patients who have been referred to the Charité - University Medicine Berlin for suspected SLE between October 2015 and September 2020. The study was approved by the local ethics committee (EA2/105/18) and written informed consent was obtained from all participants. Patients were stratified into two groups: A) SLE according to EULAR/ACR 2019 classification criteria [6] or B) SLE-mimicking conditions. The disease activity was determined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) [7]. Patients pre-treated with a prednisolone dosage exceeding 100 mg/day were excluded from the study as glucocorticoids can suppress the IFN signature in a dose- and time-dependent manner.

#### Biomarker analysis

Measurement of SIGLEC1 was described elsewhere and values with a cut-off above 2500 antigens per monocyte were regarded as positive [8].

#### Statistical analysis

Statistical analysis was performed by using GraphPad Prism 8.4.3. The Fisher's exact test was used for nominal data. Mann-Whitney-U test (non-parametric) or the unpaired T-test (parametric) were performed for continuously distributed variables. To investigate the SIGLEC1 values during follow-up in SLE patients the Friedmann and Dunn's multiple comparisons test was used. A p-value of < 0.05 was considered statistically significant. All statistical tests were performed two-sided. ROC analysis was performed for the parameters SIGLEC1, anti-nuclear antibodies (ANA), anti-double-stranded (ds)DNA antibodies, serum complement factors C3 and C4 to evaluate their diagnostic performance. Areas under the curves were compared using the DeLong test [9].

# **RESULTS**

# SIGLEC1 is significantly increased in newly diagnosed SLE and has a high negative predictive value

From 232 patients with suspected SLE referred to our institution, 76 (32.8%) patients were diagnosed with SLE according to the EULAR/ACR 2019 SLE classification criteria. Details of their demographics, organ manifestations and disease activity are provided in Table S1, and diagnosis of the remaining 156 patients with SLE-mimicking conditions are provided in Table S2. SIGLEC1 values were significantly higher in patients with SLE compared to patients without SLE (median MFI 10831 vs. 1341, p<0.0001) (Figure 1).

75 of 76 newly diagnosed lupus patients had a threshold value above 2500 molecules per monocyte. Notably, the one lupus patient with a negative SIGLEC1 had received hydroxychloroquine for 3 months prior to diagnosis. For SIGLEC1 values above the threshold, a sensitivity of 98.7 %, a specificity of 82.1 %, a negative predictive value (NPV) of 99.2 %, and a positive predictive value (PPV) of 72.8 % were calculated for the diagnosis of SLE. Notably, PPV and NPV depend on the prevalence of a disease. Considering the highest reported prevalence of SLE worldwide [1], the NPV and PPV was calculated to be > 99.9 % and 0.1 %, respectively.

# Comparison of the diagnostic performance of SIGLEC1 with established biomarkers

To compare the diagnostic utility of SIGLEC1 with established biomarkers, we next investigated the Likelihood ratios (LR), which are commonly used to calculate and compare the benefit of performing a diagnostic test. LR's are defined as the change in the probability of the presence or absence of a disease given a positive (LR+) or negative (LR-) test result, and may be further subdivided into four categories according to their diagnostic utility: "none", "weak", "strong" and "superior [10]. By applying these categories, we found that both, negative ANA and SIGLEC1 results were "superior" to exclude SLE, while the other biomarkers were not helpful (Table 1). Conversely, the utility of decreased C4 levels and positive anti-Sm antibodies was "superior" and those of positive anti-dsDNA antibodies and SIGLEC1 values was "strong" in confirming the suspected diagnosis of SLE, while ANA titre or decreased C3 levels were not useful.

In addition, we compared not only the performance of the tests at a given cut-off, but also across all possible readings by performing ROC curve analyses (Figure 2). Anti-Sm antibodies could not be considered because they were only measured qualitatively. Area under the curve of SIGLEC1 was highest with 0.95. Using the DeLong-Test to compare the AUC's, we found that the AUC of SIGLEC1 was significantly higher than that of the ANA (AUC=0.88, p=0.031), C3 (AUC = 0.83, p=0.001) and C4 (AUC=0.83, p=0.002). Only the AUC of anti-dsDNA antibodies (AUC=0.90, p=0.163) did not differ significantly from that of SIGLEC1.

#### Most patients retain increased IFN-I activity despite treatment

Finally, we followed the SIGLEC1 values longitudinally in a subgroup of 26 newly diagnosed SLE patients, from which 6 months follow-up data were available. In these patients, SIGLEC1 values decreased from a median of 10397 at baseline to 8500 at 3 months and 5799 at 6 months of follow-up, respectively (Fig. S1). Nevertheless, IFN-I pathway activation remained detectable in 18 of 26 (69 %) of patients and only 8 of 26 (31 %) of patients experienced complete regression of elevated SIGLEC1 levels after 6 months of follow up. Both groups did not significantly differ in clinical disease activity by means of SLEDAI (unpaired t test, p= 0.563). Fig. S2 shows the SLEDAI of these patients over time.

# **DISCUSSION**

In this study, the potential diagnostic utility of the IFN-I biomarker SIGLEC1 for the diagnosis of SLE was investigated in an inception cohort of 76 patients with newly diagnosed SLE and 156 patients with SLE-mimicking conditions. Our data show that negative values of SIGLEC1 at the disease onset are a powerful diagnostic tool to exclude SLE in suspected cases.

Although activation of the IFN pathway in SLE is well recognized, little is known about the diagnostic value of IFN biomarkers. Feng et al. investigated the diagnostic utility of five IFN-stimulated genes for the diagnosis of SLE in 69 pretreated patients with a disease duration of up to 22 years, and described a sensitivity and specificity between 70 and 80 % depending on the cut-off values used [11]. Yuan et al. described a sensitivity of 89 % and a specificity of 69 % for interferon-stimulated gene 15 in an inception cohort of 28 newly diagnosed SLE patients [12]. However, both studies did not compare the diagnostic utility of such IFN biomarkers with established SLE biomarkers.

Increased SIGLEC1 values were detected in virtually all newly diagnosed SLE patients. As a result, a very high negative predictive value of > 99 % and negative likelihood ratio of 0.02 for SIGLEC1 testing was calculated, suggesting that a negative test result allows to exclude SLE with a high probability. The diagnostic benefit of a normal SIGLEC1 value in excluding SLE is comparable to that for a negative ANA test in suspected SLE, to a negative D-dimer for suspected deep venous thrombosis or a negative CRP for suspected giant cell arteritis [13]. Our data suggest that validated, worldwide available interferon biomarkers may further improve diagnostic procedures and, potentially, classification of SLE [14]. With a sensitivity of nearly 100 % in juvenile dermatomyositis [15], a sensitivity of 100 % in monogenic interferonopathies [16], and a sensitivity of > 95 % in early SARS-CoV2 infection [17], SIGLEC1 may also provide a valuable screening tool for other disorders associated with increased IFN-I activity.

The specificity of SIGLEC1 for diagnosing SLE was unexpectedly high, which may be explained by a stringent pre-selection of patients by referral to a tertiary hospital. However, elevated SIGLEC1 values are also detectable in other rheumatic musculoskeletal diseases such as Sjogren's syndrome [18], myositis [15] and viral infections such as HIV [19] or SARS-CoV2 [17].

This study has certain limitations. First, the number of included patients in our inception cohort was limited and included a subset of patients who were pre-treated. Second, our data were collected retrospectively in a single centre and validation of our results in a multicentre study is needed. Finally, this study lacks inclusion of other biomarkers established for IFN-I pathway activation.

In conclusion, our data indicate that IFN-I pathway activation is detectable in nearly all patients at onset of SLE, and identifies the interferon biomarker SIGLEC1 as a powerful diagnostic tool to exclude SLE in suspected cases.

# Key Messages

### What is already known about this subject?

⇒ The activity of type I interferon has been extensively studied in SLE over the past decades, but the diagnostic utility of IFN biomarkers in suspected SLE has been poorly evaluated.

### What does this study add?

- ⇒ At the time of diagnosis, virtually all SLE patients have increased IFN-I activity as measured by SIGLEC1.
- ⇒ The negative predictive value of a normal SIGLEC1 expression for exclusion of SLE is comparable to that of a negative ANA test.
- ⇒ Although SIGLEC1 levels decrease significantly with treatment, the majority of SLE patients retain elevated SIGLEC1 expression after six months.

#### How might this impact on clinical practice or future developments?

⇒ The widespread use of easily measurable, validated IFN biomarkers would improve the diagnosis of diseases with increased IFN-I activity in general and SLE in particular.

**Acknowledgements** We thank all the patients who participated.

**Contributors** Study design: RB, TA. Sample collection: LZP, TA, RB, AVS, TK, PE, LO, MB, TD, US, TR, FH, GB. Data analysis: LZP, NU, CM, JK, RB, TA. Tables and figure: LZP, RB, TA. Data interpretation: LZP, RB, TD, TA. Writing of the manuscript: RB, LZP. Critical proofreading of the manuscript: all authors.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

**Ethics approval:** The present study was approved by the ethics committee of the Charité -Universitätsmedizin Berlin under EA2/105/18. All patients gave written informed consent. Patients were not involved in the study planning.

**Data availability statement:** The data is available upon reasonable request from the corresponding author.

#### References

- 1. Ward MM: Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. *J Womens Health (Larchmt)* 2004, 13(6):713-718.
- 2. Biesen R, Demir C, Barkhudarova F, Grun JR, Steinbrich-Zollner M, Backhaus M, Haupl T, Rudwaleit M, Riemekasten G, Radbruch A *et al*: **Sialic acidbinding lg-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.** *Arthritis Rheum* **2008, <b>58**(4):1136-1145.
- 3. Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A *et al*: **IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus**. *Ann Rheum Dis* 2013, **72**(10):1639-1645.
- 4. Rose T, Grutzkau A, Klotsche J, Enghard P, Flechsig A, Keller J, Riemekasten G, Radbruch A, Burmester GR, Dorner T *et al*: **Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study**. *Rheumatology* (Oxford) 2017, **56**(9):1618-1626.
- 5. Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U *et al*: **Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus**. *N Engl J Med* 2020, **383**(12):1149-1155.
- 6. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL *et al*: **2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus**. *Annals of the Rheumatic Diseases* 2019, **78**(9):1151-1159.
- 7. Gladman DD, Ibanez D, Urowitz MB: **Systemic lupus erythematosus disease activity index 2000**. *J Rheumatol* 2002, **29**(2):288-291.
- 8. Stuckrad SLV, Klotsche J, Biesen R, Lieber M, Thumfart J, Meisel C, Unterwalder N, Kallinich T: **SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus**. *Lupus* 2020, **29**(14):1914-1925.
- DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988, 44(3):837-845.
- 10. Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994, 271(9):703-707.
- 11. Feng X, Huang J, Liu Y, Xiao L, Wang D, Hua B, Tsao BP, Sun L: Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus. *Clin Rheumatol* 2015, **34**(1):71-79.
- 12. Yuan Y, Ma H, Ye Z, Jing W, Jiang Z: Interferon-stimulated gene 15 expression in systemic lupus erythematosus: Diagnostic value and association with lymphocytopenia. Z Rheumatol 2018, 77(3):256-262.
- 13. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS: Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of

- arteritic from non-arteritic anterior ischemic optic neuropathy. *Eur J Ophthalmol* 2004, **14**(3):245-257.
- 14. Wang B, Chen S, Zheng Q, Gao Z, Chen R, Xuan J, Liu Y, Shi G:

  Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus. *Ann Rheum Dis* 2019.
- 15. Lerkvaleekul B, Veldkamp SR, van der Wal MM, Schatorje EJH, Kamphuis SSM, van den Berg JM, Muller P, Armbrust W, Vastert SJ, Wienke J et al: Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford) 2021.
- 16. Orak B, Ngoumou G, Ebstein F, Zieba B, Goetzke CC, Knierim E, Kaindl AM, Panzer A, Theophil M, Berns M *et al*: **SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies**. *Pediatr Allergy Immunol* 2021, **32**(3):621-625.
- 17. Doehn JM, Tabeling C, Biesen R, Saccomanno J, Madlung E, Pappe E, Gabriel F, Kurth F, Meisel C, Corman VM et al: CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. Infection 2021, 49(4):757-762.
- 18. Rose T, Szelinski F, Lisney A, Reiter K, Fleischer SJ, Burmester GR, Radbruch A, Hiepe F, Grutzkau A, Biesen R *et al*: **SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome**. *RMD Open* 2016, **2**(2):e000292.
- 19. Izquierdo-Useros N, Lorizate M, McLaren PJ, Telenti A, Krausslich HG, Martinez-Picado J: HIV-1 capture and transmission by dendritic cells: the role of viral glycolipids and the cellular receptor Siglec-1. *PLoS Pathog* 2014, **10**(7):e1004146.

# Tables:

Table 1										
Biomarker	Cut- off	Sensitivity (%)	Specificity (%)	Negative predictive value (%)	Positive predictive value (%)	Negative Likelihood ratio	Positive Likelihood ratio	Relevance for rule out	Relevance for rule in	Diagnostic odds ratio
ANA (titre)	1:80	100.0	45.8	100.0	47.5	0.00	1.85	superior	none	*
Anti- dsDNA-Ab (IU/I)	20	81.4	84.2	90.4	71.3	0.22	5.15	weak	strong	23.22
Anti-Sm- Ab (+/-)	neg.	20.0	98.7	73.2	87.5	0.81	15.29	none	superior	18.98
C3 (mg/l)	900	65.8	82.6	82.6	65.8	0.41	3.78	weak	weak	9.13
C4 (mg/l)	100	39.5	97.3	75.8	88.2	0.62	14.63	none	superior	23.53
SIGLEC1 (antigens/ monocyte)	2500	98.7	82.1	99.2	72.8	0.02	5.51	superior	strong	348.23

Table 1: Diagnostic performance of SIGLEC1 compared to established biomarkers of SLE

The diagnostic benefit of a test can be roughly graduated according to the likelihood ratio (LR) in superior (LR+>10; LR-<0.1); strong (5<LR+<10; 0.1<LR-<0.2); weak (2<LR+<5; 0.2<LR-<0.5) and none (1<LR+<2; 0.5<LR-<1). Diagnostic odds ratio is calculated by quotient of LR+ and LR-. \* Not applicable due to division by zero.

Disease	SLE (n=76)	SLE-mimicking conditions (n=156)	p-value
Female (%)	86.8	88.5	ns
Age, median years (range)	33.0 (3-76)	38.0 (17-83)	0.004
Therapy (%)			
Therapy naive	56.6	85.3	0.001
Prednisolone dose mg/d median	0	0	< 0.001
(range)	(0-100)	(0-30)	
Prednisolone ≤ 7,5 mg /d	15.8	5.8	0.043
Prednisolone > 7,5 mg/d	17.1	3.2	<0.001
Hydroxychloroquine	15.8	6.4	0.017
Azathioprine	2.6	1.9	ns
Methotrexate	3.9	1.9	ns
Mycophenolate Mofetil	2.6	0.0	ns
Cyclophosphamide	2.6	0.0	ns
Laboratory values			
SIGLEC1 positive (>2500) (%)	98.7	18.0	<0.001
Median	10813	1341	<0.001
(range)	(2099-29314)	(1200-14129)	
ANA positive (≥1:160) (%)	100	54.2	<0.001
Median	1:2560	1:160	<0.001
(range)	(160-10240)	(0-10240)	
Anti-Sm Ab positive (%)	20.0	1.3	<0.001
Anti-dsDNA Ab positive (%)	81.4	15.6	< 0.001
Median	87.5	10.1	< 0.001
(range)	(3.8-200)	(0-200)	
Low C3 mg/l (<900) positive (%)	65.8	17.4	< 0.001
Median	815.0	1090.0	<0.001
(range)	(80.0-1570.0)	(650.0-8460)	
Low C4 mg/l (<100) positive (%)	39.5	2.7	<0.001
Median	110.0	230.0	<0.001
(range)	(20.0-380.0)	(20.0-550.0)	
Clinical characteristics (%)			
Fatigue	72.7	37.1	<0.001
Arthralgias	68.0	57.8	ns
Arthritis	48.0	5.2	<0.001
Raynaud	42.2	17.6	<0.001
Alopecia	41.7	18.4	<0.001
Fever	40.5	7.2	<0.001
Rash	40.0	5.3	<0.001
Photosensitivity	39.7	11.3	<0.001
Myalgias	32.4	13.9	0.002
Renal Involvement	26.3	1.9	<0.001
Pleuritis	24.0	5.8	<0.001
Sicca	23.6	20.0	ns
Oral ulcer	22.7	8.7	0.006
Pericarditis	12.0	5.8	ns
Vasculitis	9.3	1.3	0.006
Myositis	6.8	2.0	ns
CNS Symptoms	5.3	3.9	ns
SLEDAI 2K median	8	-	-
(range)	(0-27)		

**Table S1:** Patient characteristics. Nominal data like clinical characteristics were compared by

Fisher's exact test. Otherwise, Mann-Whitney-U test or unpaired t-test were performed.

Diagnosis of SLE-mim	icking conditions	SIGLEC1	SIGLEC1	p-value
patients (n=156)	icking conditions	positive values median (range)	negative values median (range)	p-value
No Final Diagnosis (Ex and musculoskeletal d		8 % 5800 (2944-14129)	92 % 1200 (1200-2373)	<0.001
Rheumatic and muscu (n=63)	loskeletal diseases			
(1.1–00)	Undifferentiated Connective Tissue Disease (UCTD) (n=30)	27 % 6596 (2529- 10536)	73 % 1261 (1200- 2215)	<0.001
	Mixed Connective Tissue Disease (MCTD) (n=7)	57 % 8814 (3700- 10013)	43 % 1434 (1293- 2239)	0.018
	Sjögren Syndrome (n=5)	80 % 6257 (2668- 12320)	20 % 1200	0.320
	Primary Anti- Phospholipid Syndrome (n=1)	0 %	100 % 1200	/
	Felty Syndrome (n=1)	100 % 3960	0 %	/
	Sarcoidosis (n=1)	0 %	100 % 1450	/
	Fibromyalgia (n=1)	0 %	100 % 1740	/
	Reactive Arthritis (n=2)	0 %	100 % 1722 (1200- 2244)	/
	Rheumatoid Arthritis (n=4)	25 % 10203	75 % 1200 (1200- 1959)	0.003
	Psoriatic Arthritis (n=2)	0 %	100 % 1295 (1272- 1317)	/
	Gonarthritis (n=2)	0 %	100 % 1367 (1200- 1533)	/
	Vasculitis (n=3)	0 %	100 % 1389 (1200- 1391)	/
	IgA Nephropathy (n=1)	100 % 10380	0 %	/
	Familial Mediterranean Fever (n=1)	0 %	100 % 1277	/
	IgG4-related Disease (n=1)	0 %	100 % 1752	/
	Discoid Lupus (n=1)	0 %	100 % 1200	/
Other organ specific d		0.04	100.51	
	Inflammatory Bowel Disease (n=1)	0 %	100 % 1507	/
	Primary ITP (n=1)	0 %	100 % 1200	/
	Amyloidosis (n=1)	0 %	100 % 1200	/
	Hashimoto Thyroiditis (n=4)	25 % 2734	75 % 1200 (1200- 1200)	/
	Celiac Disease (n=2)	0 %	100 % 1268 (1335- 1200)	/
	Multiple sclerosis (n=1)	0 %	100 % 1817	/

		Uncertain Autoimmune Disease (n=2)	0 %	100 % 1878 (1716- 2039)	/
Bacterial (n=2)	Infection		100 % 6450 (3145-9755)	0 %	/

**Table S2:** Patient characteristics in the cohort of SLE-mimicking conditions. Mann Whitney-U test or unpaired t-test were performed.

# Figures:

**Figure 1:** SIGLEC1 expression levels, analysed with flow cytometry on freshly isolated monocytes, are presented in patients with newly diagnosed SLE (n=76) and SLE-mimicking conditions (No SLE, n=156). For statistical analysis, the Mann-Whitney-U test was used. Median values and interquartile range are shown.

**Figure 2:** ROC curves analysis of ANA, SIGLEC1, anti-dsDNA antibodies, as well as C4 and C3 levels in a cohort of 76 newly diagnosed SLE patients and 156 SLE-mimicking conditions.

**Figure S1**: SIGLEC1 levels in 26 SLE patients over time after initial diagnosis. 0= time of diagnosis, 3=after three months, 6= after six months. For statistical analysis, the Friedmann test (p=0.0001) and the Dunn's multiple comparisons test was used: 0-3M p=0.004; 0-6: p=0.001; 3-6: p>0.999. The read dotted line resembles change in median values over time.

**Figure S2:** SLEDAI Follow-Up 0 months, 3 months, and six months in 26 SLE patients. Statistical analysis using non-parametric Friedman test p=0.0001 and Dunn's multiple comparisons test: 0-3 months: p=0.0457, 0-6 months: p=0.0005, 3-6 months: p= 0.7155. The read dotted line resembles change in median values over time.







